ENXTPA:SANPharmaceuticals
Could Sanofi’s (ENXTPA:SAN) Expanded Infant Vaccine Approval Reinforce Its Vaccines-Led Investment Story?
In late July 2026, the European Commission approved Sanofi’s MenQuadfi meningococcal vaccine for use in EU infants from six weeks of age, extending coverage against serogroups A, C, W, and Y and aligning dosing with routine pediatric schedules.
This broadened indication gives Sanofi an earlier entry point into infant immunization programs, potentially deepening its vaccines footprint in a high‑need, high‑risk population.
Next, we’ll examine how gaining infant approval for MenQuadfi across...